SomaLogic, Inc. (NASDAQ:SLGC) Q3 2023 Earnings Call Transcript

Unidentified Analyst: It’s Paul on for Dan. Apologies if this has been asked. I’m having trouble hearing, but I think the audio [indiscernible]. Just wondering in terms of setting up these authorized sites, now that you’re up to 14 becoming, I guess, a little more frequent. Can you talk about — are you starting to see any improvement in terms of faster pace of training or customers staying up to speed and sort of in terms of the normalized pull-through. Is that kind of something that you’re seeing as more and more authorized sites are getting out there? Or is it just more status quo as new customers [indiscernible]?

Adam Taich : No, I think [indiscernible] as we learn [indiscernible]. We continue to increase in the site [indiscernible].

Unidentified Analyst: Okay. Great. And then the last one is in terms of the guidance raise, is that something that — is there a specific geography that’s contributed more so to that? Or you’re seeing more strength than you expected a quarter ago or is that relatively broad-based?

Adam Taich : It’s fairly broad based, to be honest with you. It isn’t any ERP. In particular, I think [indiscernible] so what we’re seeing is really more broad-based growth as we extend our [indiscernible] in Europe historically, we’re seeing really nice uptick in [indiscernible].

Operator: I would now like to turn the call back over to Adam Taich for closing remarks.

Adam Taich : Great. Thanks, Shannon. And apologies for a little bit of technical difficulty right at the Q&A. I hope it’s audible. I just really want to thank you for your time and your efforts to join this call. And we look forward to another strong quarter and closing the merger with Standard BioTools. Thank you so much.

Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect.